Sermorelin vs Tesamorelin
A side-by-side research comparison of Sermorelin and Tesamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| Full name | Sermorelin Acetate (GHRH 1-29) | Tesamorelin Acetate (Egrifta) |
| Category | Growth Hormone | Growth Hormone |
| Status | Previously FDA-approved (discontinued 2008) | FDA Approved |
| Mechanism | Binds GHRH receptors on anterior pituitary via cAMP-PKA pathway. Preserves natural feedback regulation and pulsatility unlike exogenous HGH. | Binds pituitary GHRH receptors with enhanced affinity via hexenoic acid modification. Effective at mobilizing visceral fat via GH-mediated lipolysis. |
| Molecular weight | 3,358 Da | 5,136 Da |
| Half-life | 10-20 minutes | 26-38 minutes |
| Bioavailability | Moderate (SubQ) | High (SubQ) |
| Typical dose | 200-300 mcg | 2 mg |
| Frequency | Once daily before bed | Once daily |
| Route | Subcutaneous injection | Subcutaneous injection |
Sermorelin reported benefits
- Natural GH pulsatility preserved
- Improved sleep quality
- Body composition improvement
- Skin elasticity
- Long safety record
Tesamorelin reported benefits
- Visceral fat reduction (up to 18%)
- FDA-approved safety
- Improved lipid panels
- Cognitive benefits (emerging)
- No significant IGF-1 overshoot
Related comparisons
Research and educational reference only. Not medical advice.